Abstract
Introduction
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a costimulatory molecule expressed by activated T cells. This study was performed to investigate the allele and genotype frequencies of CTLA4 gene polymorphisms in Iranian patients with ankylosing spondylitis (AS).
Methods
One hundred and fifty-seven patients with AS and 103 controls were included in this study. Polymorphisms of CTLA4 gene at positions +49 (in exon 1), −318, and −1,147 (in the promoter region) were studied on the genomic DNA using PCR restriction fragment-length polymorphism method.
Results
The frequencies of the T allele at position −1147 in the patients with AS was significantly increased in comparison with the control group (11% vs. 5%, P = 0.004); whereas the frequencies of C allele at the same position were significantly decreased in the patient group (89% vs. 95%, P = 0.004). Comparison of genotype frequencies at this position showed that the frequency of CT genotype in comparison with other genotypes was overrepresented in the patient group (20% vs. 8%, P = 0.012), while the CC genotype in comparison with other genotypes was decreased (79% vs. 91%, P = 0.012). There was no significant difference on frequencies of genotypes at the positions −318 and +49.
Conclusion
This study could suggest an association between specific allele in the promoter region of CTLA4 gene and AS disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nicknam MH, Mahmoudi M, Amirzargar AA, Ganjalikhani Hakemi M, Khosravi F, Jamshidi AR, et al. Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis. Iran J Allergy Asthma Immunol. 2008;7(1):19–24.
Nicknam MH, Mahmoudi M, Amirzargar AA, Jamshidi AR, Rezaei N, Nikbin B. HLA-B27 subtypes and tumor necrosis factor alpha promoter region polymorphism in Iranian patients with ankylosing spondylitis. Eur Cytokine Netw. 2009;20(1):17–20.
Gonzalez S, Garcia-Fernandez S, Martinez-Borra J, Blanco-Gelaz MA, Rodrigo L, Sanchez del Rio J, et al. High variability of HLA-B27 alleles in ankylosing spondylitis and related spondyloarthropathies in the population of northern Spain. Hum Immunol. 2002;63(8):673–6.
Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondyloarthropathies: to lump or split? Ann Rheum Dis. 2005;64(Suppl 2):ii9–13.
Akkoc N, Khan MA. Etiopatogenic role of HLA-B27 alleles in ankylosing spondylitis. APLAR J Rheumatol. 2005;8:146–53.
Harper K, Balzano C, Rouvier E, Matti MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol. 1991;147:1037–44.
Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996;183:2541–50.
Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol. 1999;29(11):3596–602.
Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, et al. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Hum Mol Genet. 1999;8(7):1195–9.
Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol. 2008;29(6):272–9.
Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423(6939):506–11.
Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases—a general susceptibility gene to autoimmunity? Genes Immun. 2000;1(3):170–84.
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–90.
Harbo HF, Celius EG, Vartdal F, Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens. 1999;53:106–10.
Heward J, Gordon C, Allahabadia A, Barnett AH, Franklyn JA, Gough SC. The A-G polymorphism in exon 1 of the CTLA-4 gene is not associated with systemic lupus erythematosus. Ann Rheum Dis. 1999;58:193–5.
Kaijzel EL, Brinkman BM, van Krugten MV, Smith L, Huizinga TW, Verjans GM, et al. Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis. Hum Immunol. 1999;60(2):140–4.
Lee YH, Ji JD, Sohn J, Song GG. Polymorphsims of CTLA-4 exon 1 +49, CTLA-4 promoter −318 and Fas promoter −670 in spondyloarthropathies. Clin Rheumatol. 2001;20(6):420–2.
Martin TM, Bye L, Modi N, Stanford MR, Vaughan R, Smith JR, et al. Genotype analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and PTPN22, in an acute anterior uveitis cohort. Mol Vis. 2009;15:208–12.
Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 of exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. J Immunol. 2000;165:6606–11.
Acknowledgments
We thank the Iranian Ankylosing Spondylitis association, especially Mrs. Farzaneh Fattahi, for the valuable collaboration.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Azizi, E., Massoud, A., Amirzargar, A.A. et al. Association of CTLA4 Gene Polymorphism in Iranian Patients with Ankylosing Spondylitis. J Clin Immunol 30, 268–271 (2010). https://doi.org/10.1007/s10875-009-9356-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-009-9356-y